{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:38Z","timestamp":1786984298538,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.amjcard.2024.10.029","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:45:09Z","timestamp":1730270709000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Comparative Influences of Beta blockers and Verapamil on Cardiac Outcomes in Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-2955","authenticated-orcid":false,"given":"Giuseppe","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Chiarito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Puscas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Reant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hag\u00e8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.10.029_bib0001","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery risk development in (young) adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0002","first-page":"3503","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0003","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0004","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.CIR.35.5.847","article-title":"Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade","volume":"35","author":"Cohen","year":"1967","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0005","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.38.5.846","article-title":"Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol","volume":"38","author":"Flamm","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0006","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/hrt.32.6.804","article-title":"Long-term propranolol therapy in muscular subaortic stenosis","volume":"32","author":"Adelman","year":"1970","journal-title":"Br Heart J"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0007","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9149(73)90012-X","article-title":"Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy","volume":"31","author":"Stenson","year":"1973","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0008","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0009","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0011","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/hrt.48.3.204","article-title":"Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs","volume":"48","author":"Alvares","year":"1982","journal-title":"Br Heart J"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0012","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0013","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0014","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","article-title":"Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy","volume":"64","author":"Epstein","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0016","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0002-9149(81)90086-2","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration","volume":"48","author":"Rosing","year":"1981","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0017","doi-asserted-by":"crossref","first-page":"185B","DOI":"10.1016\/0002-9149(85)90630-7","article-title":"Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy","volume":"55","author":"Rosing","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijcard.2018.09.083","article-title":"Influence of centre expertise on the diagnosis and management of hypertrophic cardiomyopathy: a study from the French register of hypertrophic cardiomyopathy (REMY)","volume":"275","author":"Mirabel","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0019","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015473","article-title":"Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a New Era in clinical testing?","volume":"9","author":"Mazzarotto","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0021","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0022","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/BF02026500","article-title":"Hypertrophic cardiomyopathy: long-term effects of propranolol versus verapamil in preventing sudden death in \u201clow-risk\u201d patients","volume":"4","author":"Pelliccia","year":"1990","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0023","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0024","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0025","first-page":"e43197","article-title":"Metoprolol or verapamil in the management of patients with hypertrophic cardiomyopathy: a systematic review","volume":"15","author":"Taha","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0026","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/hrt.2006.089656","article-title":"Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure","volume":"93","author":"Raphael","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0027","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ejhf.2923","article-title":"NYHA classification for decision-making in heart failure: time to reassess?","volume":"25","author":"Zimerman","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0028","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (Explorer-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.10.029_bib0030","doi-asserted-by":"crossref","first-page":"11957","DOI":"10.1038\/s41598-017-12289-4","article-title":"Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924007690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924007690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T08:44:56Z","timestamp":1734425096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924007690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"alternative-id":["S0002914924007690"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.10.029","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Influences of Beta blockers and Verapamil on Cardiac Outcomes in Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}